Wedbush Reiterates an 'Outperform' on Medivation (MDVN); Raising PT on Early Approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Leerink Swann Maintains an 'Outperform' on Medivation (MDVN); Number of Advantages Based on Labeling
September 4, 2012 10:51 AM EDTLeerink Swann maintains an 'Outperform' on Medivation (NASDAQ: MDVN) price target of $122.00.
Analyst, Howard Liang, said, "Based on our detailed comparison of product labels, we believe that the Xtandi label has a number of advantages over Zytiga (NYSE:... More
Brean Murray Carret & Co. Maintains a 'Buy' on Medivation (MDVN); Adjusting Numbers on Xtandi Approval
September 4, 2012 8:52 AM EDTBrean Murray Carret & Co. maintains a 'Buy' on Medivation (NASDAQ: MDVN) price target of $125.00 (from $105.00).
Analyst, MDVN's XTANDI (enzalutamide; MDV3100) was approved by the FDA on August 31 for patients with metastic castration-resistant prostate cancer who have previously received docetaxel, but we... More
Jefferies Reiterates a 'Buy' on Medivation (MDVN); Xtandi Approved Early
September 4, 2012 7:17 AM EDTJefferies reiterates a 'Buy' on Medivation (NASDAQ: MDVN) price target of $122.00 (from $113.00).
Analyst, Biren Amin, said, "Xtandi (enzalutamide) approval came ~3 months ahead of its November PDUFA date, and a slight positive on ~1 addl qtr of sales. The label was generally in-line... More
Medivation (MDVN) Up ~8% Following Halt for Xtandi Approval
August 31, 2012 4:01 PM EDTMedivation, Inc. (Nasdaq: MDVN) is now up 7.8 percent on the session after resumption.
Shares were up slightly before being halted for FDA approval of Xtandi for late stage prostate cancer.... More
FDA Approves Medivation (MDVN), Astellas' Xtandi for Late Stage Prostate Cancer
August 31, 2012 1:19 PM EDTBelow is the press release from the FDA on approval for Medivation (Nasdaq: MDVN) and Astellas' Xtandi for late stage prostate cancer:
FDA approves new treatment for a type of late stage prostate cancer
The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.
Approved for prostate cancer patients previously treated with docetaxel, another anti-cancer treatment, Xtandi was reviewed under the FDAs priority... More
